188 related articles for article (PubMed ID: 11961132)
1. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Balzarini J; Sienaert R; Liekens S; Van Kuilenburg A; Carangio A; Esnouf R; De Clercq E; McGuigan C
Mol Pharmacol; 2002 May; 61(5):1140-5. PubMed ID: 11961132
[TBL] [Abstract][Full Text] [Related]
2. Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replication.
Balzarini J; McGuigan C
J Antimicrob Chemother; 2002 Jul; 50(1):5-9. PubMed ID: 12096000
[TBL] [Abstract][Full Text] [Related]
3. Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase.
Sienaert R; Naesens L; Brancale A; De Clercq E; McGuigan C; Balzarini J
Mol Pharmacol; 2002 Feb; 61(2):249-54. PubMed ID: 11809847
[TBL] [Abstract][Full Text] [Related]
4. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides.
Andrei G; Sienaert R; McGuigan C; De Clercq E; Balzarini J; Snoeck R
Antimicrob Agents Chemother; 2005 Mar; 49(3):1081-6. PubMed ID: 15728906
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides.
Balzarini J; McGuigan C
Biochim Biophys Acta; 2002 Jul; 1587(2-3):287-95. PubMed ID: 12084470
[TBL] [Abstract][Full Text] [Related]
6. Mutations distal to the substrate site can affect varicella zoster virus thymidine kinase activity: implications for drug design.
El Omari K; Liekens S; Bird LE; Balzarini J; Stammers DK
Mol Pharmacol; 2006 Jun; 69(6):1891-6. PubMed ID: 16556772
[TBL] [Abstract][Full Text] [Related]
7. 2'-Fluorosugar analogues of the highly potent anti-varicella-zoster virus bicyclic nucleoside analogue (BCNA) Cf 1743.
McGuigan C; Derudas M; Quintiliani M; Andrei G; Snoeck R; Henson G; Balzarini J
Bioorg Med Chem Lett; 2009 Nov; 19(22):6264-7. PubMed ID: 19833513
[TBL] [Abstract][Full Text] [Related]
8. Potential of bromovinyldeoxyuridine in anticancer chemotherapy.
De Clercq E
Anticancer Res; 1986; 6(4):549-56. PubMed ID: 3752935
[TBL] [Abstract][Full Text] [Related]
9. (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU).
De Clercq E
Med Res Rev; 2005 Jan; 25(1):1-20. PubMed ID: 15389733
[TBL] [Abstract][Full Text] [Related]
10. β-l-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (l-BHDU) prevents varicella-zoster virus replication in a SCID-Hu mouse model and does not interfere with 5-fluorouracil catabolism.
De C; Liu D; Zheng B; Singh US; Chavre S; White C; Arnold RD; Hagen FK; Chu CK; Moffat JF
Antiviral Res; 2014 Oct; 110():10-9. PubMed ID: 25051026
[TBL] [Abstract][Full Text] [Related]
11. [Molecular toxicological mechanism of the lethal interactions of the new antiviral drug, sorivudine, with 5-fluorouracil prodrugs and genetic deficiency of dihydropyrimidine dehydrogenase].
Watabe T; Ogura K; Nishiyama T
Yakugaku Zasshi; 2002 Aug; 122(8):527-35. PubMed ID: 12187768
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and pharmacological characteristics of the bicyclic nucleoside analogues (BCNAs) as highly selective inhibitors of varicella-zoster virus (VZV).
Sienaert R; Naesens L; Brancale A; Carangio A; Andrei G; Snoeck R; Van Kuilenburg A; De Clercq E; McGuigan C; Balzarini J
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):995-7. PubMed ID: 14565329
[No Abstract] [Full Text] [Related]
13. The development of BVDU: An odyssey.
De Clercq E
Antivir Chem Chemother; 2023; 31():20402066231152971. PubMed ID: 36710501
[TBL] [Abstract][Full Text] [Related]
14. Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues.
De Clercq E
Med Res Rev; 2003 May; 23(3):253-74. PubMed ID: 12647310
[TBL] [Abstract][Full Text] [Related]
15. Inactivity of the bicyclic pyrimidine nucleoside analogues against simian varicella virus (SVV) does not correlate with their substrate activity for SVV-encoded thymidine kinase.
Sienaert R; Andrei G; Snoeck R; De Clercq E; McGuigan C; Balzarini J
Biochem Biophys Res Commun; 2004 Mar; 315(4):877-83. PubMed ID: 14985094
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
De Clercq E; Desgranges C; Herdewijn P; Sim IS; Jones AS; McLean MJ; Walker RT
J Med Chem; 1986 Feb; 29(2):213-7. PubMed ID: 3005566
[TBL] [Abstract][Full Text] [Related]
17. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.
De Clercq E
Biochem Pharmacol; 2004 Dec; 68(12):2301-15. PubMed ID: 15548377
[TBL] [Abstract][Full Text] [Related]
18. Phosphorolysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and other 5-substituted-2'-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets.
Desgranges C; Razaka G; Rabaud M; Bricaud H; Balzarini J; De Clercq E
Biochem Pharmacol; 1983 Dec; 32(23):3583-90. PubMed ID: 6651877
[TBL] [Abstract][Full Text] [Related]
19. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil.
Kanamitsu SI; Ito K; Okuda H; Ogura K; Watabe T; Muro K; Sugiyama Y
Drug Metab Dispos; 2000 Apr; 28(4):467-74. PubMed ID: 10725316
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
De Clercq E; Descamps J; Ogata M; Shigeta S
Antimicrob Agents Chemother; 1982 Jan; 21(1):33-8. PubMed ID: 6282207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
